The ACTIMIS clinical trial evaluating glenzocimab in combination with the reference treatment in patients presenting with AIS has demonstrated a favorable safety profile of glenzocimab, as well as a significant reduction in the number of intracerebral hemorrhages and mortality in the group treated with glenzocimab
The benefit of glenzocimab was more pronounced in patients having undergone a mechanical thrombectomy after an initial treatment by a thrombolytic agent. (Credit: Pexels from Pixabay)
Acticor Biotech, a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today the results of its collaboration with Brainomix Limited, to further explore the imaging data using Artificial Intelligence (AI) from its phase 1b/2a ACTIMIS study.
The ACTIMIS clinical trial evaluating glenzocimab in combination with the reference treatment (thrombolysis with or without thrombectomy) in patients presenting with Acute Ischemic Stroke (AIS) has demonstrated a favorable safety profile of glenzocimab, as well as a significant reduction in the number of intracerebral hemorrhages and mortality in the group treated with glenzocimab.
To explore the mode of action of glenzocimab in the reduction of intracranial hemorrhage occurrence, a collaboration has been setup with Brainomix, a UK company specialized in the creation of AI-powered imaging biomarkers, to further analyze imaging stroke results from ACTIMIS study.
In a post-hoc analysis of the ACTIMIS study results, ischemic injury and hemorrhagic transformation volume measurements were quantified using AI-enabled Brainomix software. This provided an objective assessment of the evolution of the stroke brain injury which was associated with clinical outcome. First results using these biomarkers showed that patients treated with glenzocimab had smaller stroke lesion volumes compared to placebo-recipients (standard of care only), mainly due to a significant reduction in hemorrhagic transformation volumes. The benefit of glenzocimab was more pronounced in patients having undergone a mechanical thrombectomy after an initial treatment by a thrombolytic agent.
Yannick PLETAN, Chief Medical Officer and General Manager of Acticor Biotech, explained: “We are delighted with this collaboration with Brainomix, which enables us for the first time to analyze in greater detail the brain images of patients in the ACTIMIS study. Preliminary results seem to show that glenzocimab not only reduces the occurrence of intracranial hemorrhages, but also their volume, compared with placebo. These results support the first analyses of the ACTIMIS study and will be submitted for publication at upcoming international congresses.”
George HARSTON, Chief Medical Officer of Brainomix and Consultant Stroke Physician said: “We are excited to have partnered with Acticor Biotech to support this innovative analysis of the ACTIMIS study using our AI-powered imaging biomarkers. The Brainomix core lab analysis has helped elucidate the mechanism and demonstrate efficacy of glenzocimab. It has shown that glenzocimab reduced brain injury following thrombolysis in stroke, and identified subgroups of patients who appear to benefit most.”
Source: Company Press Release